Acute promyelocytic leukemia

Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
Health, Pharmaceutical, Gene, Syros, NASDAQ, CDK7, LinkedIn, Acute myeloid leukemia, Madison Avenue, Genome, Arsenic trioxide, RARA, Conference, Acute promyelocytic leukemia, Twitter, Investor, Webcast, Lotte New York Palace Hotel, Patient, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.
  • An archived replay of the webcast will be available for approximately 30 days following the presentation.
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 2, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Acute promyelocytic leukemia, RSU, Twitter, Acute myeloid leukemia, CDK7, Genome, Arsenic trioxide, RARA, Gene, Employment, Nasdaq, LinkedIn, Patient, Pharmaceutical industry, Syros

These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Both awards are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros 2022 Inducement Stock Incentive Plan.
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 4, 2022
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Acute myeloid leukemia, CDK7, Gene, Genome, Patient, RARA, Twitter, Arsenic trioxide, RSU, Employment, Nasdaq, LinkedIn, Acute promyelocytic leukemia, Pharmaceutical industry, Syros

Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 31,000 shares of Syros common stock to one newly hired employee in connection with the employees commencement of employment with Syros.

Key Points: 
  • Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 31,000 shares of Syros common stock to one newly hired employee in connection with the employees commencement of employment with Syros.
  • These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Retrieved on: 
Wednesday, August 3, 2022
Research, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Private Securities Litigation Reform Act, European Medicines Agency, Security (finance), Annual report, COVID-19, Marketing, Arsenic trioxide, MDS, Freedom, Union, Acute promyelocytic leukemia, Acute myeloid leukemia, Workforce, AML, Patient, Food, Compte rendu, EMA, CDK7, Azacitidine, Genome, U.S. Securities and Exchange Commission, RARA, Safety, FDA, LinkedIn, European Commission, Government, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Syros, Myelodysplastic syndrome, Gene, Twitter, Person, Royal commission, Clinical trial, NASDAQ, Population, Pharmaceutical industry, EU

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Companys application for orphan drug designation for tamibarotene for the treatment of myelodysplastic syndrome (MDS).

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Companys application for orphan drug designation for tamibarotene for the treatment of myelodysplastic syndrome (MDS).
  • Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to tamibarotene in MDS in February 2022.
  • Orphan drug designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products.
  • In addition, a positive opinion from the EMA on Syros application for orphan drug designation for tamibarotene for the treatment of MDS is not a guarantee of approval of an orphan drug designation.

Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Retrieved on: 
Tuesday, August 2, 2022
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Research, Genetics, Science, Clinical Trials, Acute promyelocytic leukemia, Genome, Twitter, Arsenic trioxide, Syros, RARA, NASDAQ, Conference, Gene, Webcast, CDK7, Patient, LinkedIn, Acute myeloid leukemia, Investor, Pharmaceutical industry

ET on Tuesday, August 9, 2022 to report its second quarter 2022 financial results and provide a corporate update.

Key Points: 
  • ET on Tuesday, August 9, 2022 to report its second quarter 2022 financial results and provide a corporate update.
  • To access the live conference call, please dial (833) 636-1323 (domestic) or (412) 902-4279 (international) and refer to the Syros Pharmaceuticals Conference Call.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .
  • Syros is redefining the power of small molecules to control the expression of genes.

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

Retrieved on: 
Tuesday, July 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Patient, Research, Register, COVID-19, Cancer, Company, Hematology, Roche, Nature, NDA, Security (finance), RARA, Securities Act of 1933, Achievement, Securities Exchange Act of 1934, Gene, Intellectual property, Prospectus, Pancreatic cancer, Proxy, Breast, SEC, Registration statement, Risk, Twitter, Forward-looking statement, LinkedIn, Acute promyelocytic leukemia, Hematological Cancer Research Investment and Education Act, Failure, Goal, AML, Sarcoma, Acute myeloid leukemia, Nasdaq, NASDAQ, Board, Review, Annual report, BRAF, LLP, Sale, U.S. Securities and Exchange Commission, Form, PIPE, Azacitidine, Prostate, Wilmer Cutler Pickering Hale and Dorr, CDK7, Government, Safety, Venetoclax, APL, Arsenic trioxide, Program, Genome, Director, Pharmaceutical industry, Bank, Management, Holding company, TYME, Piper, Syros

Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94.

Key Points: 
  • Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94.
  • The team at Syros shares our unwavering commitment to develop medicines that make a profound difference in patients lives.
  • In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYMEs expected net cash at closing and TYME stockholders are expected to receive approximately 0.4312 shares of Syros common stock for each share of TYME common stock.
  • The Registration Statement and the Joint Proxy Statement/Prospectus will contain important information about Syros, TYME, the transactions and related matters.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 1, 2022
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, RSU, Patient, LinkedIn, RARA, Acute promyelocytic leukemia, Gene, Employment, Acute myeloid leukemia, Nasdaq, CDK7, Twitter, Arsenic trioxide, Genome, Pharmaceutical industry, Syros

Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 48,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.

Key Points: 
  • Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 48,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.
  • These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022
Patient, Medication, Research, Marketing, COVID-19, Growth, Pramipexole, Company, Tax, JBM, Febuxostat, Guangdong-Hong Kong-Macau Greater Bay Area, Vaccination, Acceleration, Development, Department, Depreciation, EBITDA, Big White Duel, GMP, Acute promyelocytic leukemia, Idarubicin, Department of Health (Hong Kong), Fosun International, Fosun Pharma, Diabetes, Medical device, Conditional sentence, Greater, Dexmedetomidine, Health care, Public sector, Hospital, Board, PIC/S, HK, Analgesic, Sale, Amlodipine, The Group, University, Cardiovascular disease, Tablet, Immunity, Generic drug, Pharmaceutical industry, Vaccine, Valsartan, Group, Vaccine, Telmisartan, Brimonidine

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Syros Pharmaceuticals Implements Genedata Profiler to Accelerate Therapeutic Development for Genomically Targeted Patient Populations

Retrieved on: 
Thursday, June 23, 2022
CDK7, Arsenic trioxide, Collaboration, Intelligence, Acute promyelocytic leukemia, Gene, CEO, Cancer, Research, LinkedIn, Growth, Disease, Protein, RARA, Partnership, Twitter, ROI, Patient, Genome, D, Cell, RAR, Acute myeloid leukemia, Fine chemical, Pharmaceutical industry, Syros, Genedata

BASEL, Switzerland, June 23, 2022 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, has chosen Genedata Profiler® as its data integration and analytics platform to accelerate its translational research strategy.

Key Points: 
  • Under the terms of the agreement, Syros is licensing Genedata Profiler to speed up the development of such targeted medicines.
  • As part of the deal, Genedata also is committing consulting resources to digitalize processes specific to Syros Pharmaceuticals.
  • "To accelerate the development of medicines for genomically targeted patient populations, a computational platform is critical to support our translational and clinical research strategy," said Nancy Simonian, M.D., Chief Executive Officer of Syros.
  • "Genedata Profiler is perfectly-suited to assist emerging biopharmaceutical companies in their scientific innovation and in their quest for sustainable growth."

Syros to Present at JMP Securities Life Sciences Conference

Retrieved on: 
Wednesday, June 8, 2022
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Madison Avenue, Genome, Conference, Syros, LinkedIn, Webcast, Lotte New York Palace Hotel, Investor, RARA, Gene, Patient, Acute myeloid leukemia, NASDAQ, Twitter, CDK7, Acute promyelocytic leukemia, Arsenic trioxide, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference.
  • An archived replay of the webcast will be available for approximately 30 days following the presentation.
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.